B-cell Non-Hodgkin's lymphoma
Drug research and approvals for B-cell Non-Hodgkin's lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 529 studies of B-cell Non-Hodgkin's lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 17 drug trials for it since 2013, and FDA has 2 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 529
- Trials authorized in Canada: 17
- FDA orphan approvals: 2
- EU medicines: 0
- First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That…NCT07948733 · Phase 1 · Cellogen Therapeutics Pvt. Ltd. · starts Oct 26, 2026
- Simulation-Free Single-Fraction Radiation Therapy for Indolent LymphomaNCT07945470 · Not applicable · University Health Network, Toronto · starts Oct 9, 2026
- Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment…NCT07934537 · Phase 4 · Shanghai Tongji Hospital, Tongji University School of Medicine · starts Oct 30, 2025
- GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaNCT07910708 · Phase 1 · Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · starts Aug 4, 2026
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and…NCT07908888 · Phase 4 · The First Hospital of Jilin University · starts Oct 15, 2026
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or…NCT07892027 · Phase 2 · University of Michigan Rogel Cancer Center · starts Nov 10, 2026
- BEX101 in B-cell Non-Hodgkin's LymphomaNCT07882641 · Phase 1 / Phase 2 · Chinese PLA General Hospital · starts Oct 15, 2026
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasNCT07883135 · Phase 2 · National Research Center for Hematology, Russia · starts Sep 1, 2026
- Prospective ctDNA Testing in Large B-Cell LymphomaNCT07878351 · Not reported · Peking University People's Hospital · starts Oct 15, 2026
| Apr 29, 2026 | A phase 1/2 open-label, multi-center study to evaluate the safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-cell…GSK5926371 | GSK | Ongoing |
| Jun 20, 2025 | An open-label, multicenter, phase 1 trial to evaluate the safety, pharmakonetics, and anti-tumour activity of TLN-121 as a single agent and in combination with…TLN-121 / Cyclophosphamide / Lunsumio (mosunetuzumab) / Columvi (glofitamab) /… | Treeline Biosciences | Ongoing |
| Sep 20, 2024 | A modular phase II, single-arm, multicenter, open-label study to evaluate the efficacy and safety of AZD0486 in participants with relapsed or refractory B-cell…AZD0486 | AstraZeneca Pharmaceuticals | Ongoing |
| Mar 8, 2024 | A phase 1b multicenter, open-label, study of JNJ-90014496, an autologous CD19/CD20 bi-specific CAR-T cell therapy in adult participants with relapsed or…JNJ-90014496 | Johnson & Johnson | Ongoing |
| May 31, 2023 | A phase 1, open-label, multicenter, dose escalation study of PRT1419 injection as monotherapy or in combination with azacitidine or venetoclax in patients with…PRT1419 / Venetoclax / Azacitidine | Prelude Therapeutics | Closed |
| May 30, 2023 | A phase I cohort dose escalation and expansion trial to determine the safety, tolerance, maximum tolerated dose, and preliminary antineoplastic activity of…IKS03 | Iksuda Therapeutics Limited | Ongoing |
| Apr 11, 2022 | Long-term follow-up study for participants of kite sponsored interventional studies treated with gene modified cellsYescarta / Tecartus | Kite, A Gilead Company | Pending |
| Mar 3, 2022 | A phase 1, open-label, dose-escalation and dose-expansion study of NL-201 in patients with B-cell lymphoma, Hodgkin lymphoma, or multiple myelomaNL-201 | Neoleukin Therapeutics Inc. | Pending |
| Aug 4, 2021 | A phase Ib/II open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab with or…Mosunetuzumab (BTCT4465A; RO7030816) \ tiragolumab (RO7092284) \ atezolizumab… | Roche | Closed |
| Sep 3, 2020 | A phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory…Lisocabtagene maraleucel (JCAR017) | Bristol-Myers Squibb | Ongoing |
| Feb 19, 2002 | ZevalinTreatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients… | Acrotech Biopharma LLC | Approved |
| Nov 26, 1997 | RituxanTreatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma | Genentech, Inc. | Approved |
| Nov 27, 1998 | Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb…Treatment of B-cell non-Hodgkin's lymphoma. | Peregrine Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA